Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma

被引：9
|
作者：
Mollica, Veronica [1 ]
Di Nunno, Vincenzo [1 ]
Massari, Francesco [1 ]
机构：
[1] St Orsola Marcello Malpighi Hosp, Div Oncol, Via Albertoni 15, I-40138 Bologna, Italy
来源：
CHINESE CLINICAL ONCOLOGY | 2019年 / 8卷
关键词：
D O I：
10.21037/cco.2019.04.05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Axitinib in metastatic renal cell carcinoma
    Albiges, Laurence
    Gizzi, Marco
    Carton, Edith
    Escudier, Bernard
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (05) : 499 - 507
  • [22] Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Teh, Jiasian
    Narasimhan, Vignesh
    Schultz, Stephen
    Sathianathen, Niranjan
    Murphy, Declan G.
    EUROPEAN UROLOGY, 2019, 76 (01) : 126 - 127
  • [23] Sinus Bradycardia With Pauses Owing to Axitinib/Pembrolizumab in a Metastatic Renal Cell Carcinoma Patient
    McGreevy, Joseph W.
    Ghous, Ghulam
    Shoukat, Hafiz Muhammad Hassan
    Zafar, Muhammad Usman
    Tarar, Zahid Ijaz
    AMERICAN JOURNAL OF THERAPEUTICS, 2023, 30 (03) : E304 - E305
  • [24] Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma Comment
    Procopio, Giuseppe
    Nichetti, Federico
    Verzoni, Elena
    LANCET ONCOLOGY, 2020, 21 (12): : 1538 - 1539
  • [25] Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
    Stellato, Marco
    Buti, Sebastiano
    Maruzzo, Marco
    Bersanelli, Melissa
    Pierantoni, Francesco
    De Giorgi, Ugo
    Di Napoli, Marilena
    Iacovelli, Roberto
    Vitale, Maria Giuseppa
    Ermacora, Paola
    Malgeri, Andrea
    Maiorano, Brigida Anna
    Prati, Veronica
    Mennitto, Alessia
    Cavo, Alessia
    Santoni, Matteo
    Carella, Claudia
    Fratino, Lucia
    Procopio, Giuseppe
    Verzoni, Elena
    Santini, Daniele
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)
  • [26] A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
    Meyo, Manuela Tiako
    Chen, Jeanne
    Goldwasser, Francois
    Hirsch, Laure
    Huillard, Olivier
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2022, 18 : 683 - 698
  • [27] Myocarditis Following Pembrolizumab Plus Axitinib, and Belzutifan Plus Lenvatinib for Renal Cell Carcinoma: A Case Report
    Villatore, Andrea
    Bosi, Carlo
    Pomaranzi, Chiara
    Cigliola, Antonio
    Tateo, Valentina
    Mercinelli, Chiara
    Vignale, Davide
    Rizzo, Stefania
    Necchi, Andrea
    Peretto, Giovanni
    CARDIOVASCULAR TOXICOLOGY, 2024, 24 (11) : 1168 - 1173
  • [28] Phase lb dose-finding study of axitinib plus pembrolizumab in treatment-naive patients with advanced renal cell carcinoma
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Gupta, Shilpa
    Puzanov, Igor
    Mcdermott, David F.
    Tarazi, Jamal
    Keefe, Stephen
    Rosbrook, Brad
    Atkins, Michael B.
    BJU INTERNATIONAL, 2015, 116 : 5 - 5
  • [29] Matching-adjusted indirect comparison of pembrolizumab plus axitinib versus nivolumab plus ipilimumab for the first-line treatment of advanced/metastatic renal cell carcinoma
    Wang, Yufei
    Zhong, Yichen
    Mt-Isa, Shahrul
    Perini, Rodolfo
    Adejoro, Oluwakayode
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [30] Characteristics of patients with metastatic renal cell carcinoma who do not respond to axitinib treatment
    Ohba, Kojiro
    Osawa, Takahiro
    Kojima, Takahiro
    Hara, Tomohiko
    Sugimoto, Mikio
    Eto, Masatoshi
    Minami, Keita
    Nakai, Yasutomo
    Ueda, Kosuke
    Naito, Sei
    Nonomura, Norio
    Murai, Sachiyo
    Nishiyama, Hiroyuki
    Nakanishi, Hiromi
    Mukae, Yuta
    Mitsunari, Kensuke
    Matsuo, Tomohiro
    Imamura, Ryoichi
    Shinohara, Nobuo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, : 781 - 788
12345